The safe administration of long-acting depot antipsychotics

Research output: Contribution to journalArticle

Abstract

Injectable long-acting antipsychotics are a well-established and common treatment for schizophrenia and other mental health problems. While these medicines have traditionally been injected into the dorsogluteal muscle, the primacy of this site has been challenged over recent years, both through the emergence of the deltoid muscle as a less intrusive alternative, and through a groundswell of opinion raising concerns over the safety of injecting into the gluteal muscle. As these concerns have included calls for the dorsogluteal site to no longer be considered suitable for the administration of injections, there is a need to clarify the basis of such claims and the appropriateness of continued use of this area. Review of relevant literature allowed exploration of the evidence used in supporting these claims and identified that UK licencing agreements for these medicines fails to support such wholesale change and that there are considerable inconsistencies in the evidence presented. Recommendations are made for further study in this area and for measured change to practice if required, particularly around use of the deltoid site and for review of the licencing agreements for these medicines.

Original languageEnglish
Pages (from-to)464, 466-9
JournalBritish Journal of Nursing
Volume22
Issue number8
DOIs
Publication statusPublished - 3 Aug 2013

Fingerprint

Licensure
Antipsychotic Agents
Deltoid Muscle
Muscles
Injections
Schizophrenia
Mental Health
Safety
Therapeutics

Keywords

  • Antipsychotic Agents
  • Delayed-Action Preparations
  • Humans
  • Psychiatric Nursing
  • Psychotic Disorders

Cite this

@article{3603f70891e347fb89bfc27a0a353530,
title = "The safe administration of long-acting depot antipsychotics",
abstract = "Injectable long-acting antipsychotics are a well-established and common treatment for schizophrenia and other mental health problems. While these medicines have traditionally been injected into the dorsogluteal muscle, the primacy of this site has been challenged over recent years, both through the emergence of the deltoid muscle as a less intrusive alternative, and through a groundswell of opinion raising concerns over the safety of injecting into the gluteal muscle. As these concerns have included calls for the dorsogluteal site to no longer be considered suitable for the administration of injections, there is a need to clarify the basis of such claims and the appropriateness of continued use of this area. Review of relevant literature allowed exploration of the evidence used in supporting these claims and identified that UK licencing agreements for these medicines fails to support such wholesale change and that there are considerable inconsistencies in the evidence presented. Recommendations are made for further study in this area and for measured change to practice if required, particularly around use of the deltoid site and for review of the licencing agreements for these medicines.",
keywords = "Antipsychotic Agents, Delayed-Action Preparations, Humans, Psychiatric Nursing, Psychotic Disorders",
author = "Mark Gillespie and Alison Toner",
year = "2013",
month = "8",
day = "3",
doi = "10.12968/bjon.2013.22.8.464",
language = "English",
volume = "22",
pages = "464, 466--9",
journal = "British Journal of Nursing",
issn = "0966-0461",
publisher = "Mark Allen Healthcare",
number = "8",

}

The safe administration of long-acting depot antipsychotics. / Gillespie, Mark; Toner, Alison.

In: British Journal of Nursing, Vol. 22, No. 8, 03.08.2013, p. 464, 466-9.

Research output: Contribution to journalArticle

TY - JOUR

T1 - The safe administration of long-acting depot antipsychotics

AU - Gillespie, Mark

AU - Toner, Alison

PY - 2013/8/3

Y1 - 2013/8/3

N2 - Injectable long-acting antipsychotics are a well-established and common treatment for schizophrenia and other mental health problems. While these medicines have traditionally been injected into the dorsogluteal muscle, the primacy of this site has been challenged over recent years, both through the emergence of the deltoid muscle as a less intrusive alternative, and through a groundswell of opinion raising concerns over the safety of injecting into the gluteal muscle. As these concerns have included calls for the dorsogluteal site to no longer be considered suitable for the administration of injections, there is a need to clarify the basis of such claims and the appropriateness of continued use of this area. Review of relevant literature allowed exploration of the evidence used in supporting these claims and identified that UK licencing agreements for these medicines fails to support such wholesale change and that there are considerable inconsistencies in the evidence presented. Recommendations are made for further study in this area and for measured change to practice if required, particularly around use of the deltoid site and for review of the licencing agreements for these medicines.

AB - Injectable long-acting antipsychotics are a well-established and common treatment for schizophrenia and other mental health problems. While these medicines have traditionally been injected into the dorsogluteal muscle, the primacy of this site has been challenged over recent years, both through the emergence of the deltoid muscle as a less intrusive alternative, and through a groundswell of opinion raising concerns over the safety of injecting into the gluteal muscle. As these concerns have included calls for the dorsogluteal site to no longer be considered suitable for the administration of injections, there is a need to clarify the basis of such claims and the appropriateness of continued use of this area. Review of relevant literature allowed exploration of the evidence used in supporting these claims and identified that UK licencing agreements for these medicines fails to support such wholesale change and that there are considerable inconsistencies in the evidence presented. Recommendations are made for further study in this area and for measured change to practice if required, particularly around use of the deltoid site and for review of the licencing agreements for these medicines.

KW - Antipsychotic Agents

KW - Delayed-Action Preparations

KW - Humans

KW - Psychiatric Nursing

KW - Psychotic Disorders

U2 - 10.12968/bjon.2013.22.8.464

DO - 10.12968/bjon.2013.22.8.464

M3 - Article

VL - 22

SP - 464, 466-9

JO - British Journal of Nursing

JF - British Journal of Nursing

SN - 0966-0461

IS - 8

ER -